A meeting worth bugging!

NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Pfizer Inc said today it disagrees with the conclusions stated in a non-approvable letter it received from the U.S. Food and Drug Administration regarding parecoxib sodium, a non-narcotic injectable COX-2 selective analgesic for the treatment of acute pain.The company plans to meet with the FDA to discuss the agency's concerns. Pfizer said parecoxib is widely available worldwide, including in the European Union, mostly under the brand name Dynastat.